Arcutis Biotherapeutics, Inc.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $376.1M
- Net income
- -$16.1M
- Total assets
- $433.0M
- Market cap
- $2.7B
- Gross margin
- 90.2%
- Operating margin
- -3.3%
- Net margin
- -4.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $376.1M
- Cost of revenue
- $36.7M
- Gross profit
- $339.4M
- Operating expenses
- $351.6M
- Operating income
- -$12.2M
- Income tax
- $1.2M
- Net income
- -$16.1M
- EPS (basic)
- $-0.13
- EPS (diluted)
- $-0.13
Balance sheet
- Total assets
- $433.0M
- Current assets
- $411.2M
- Total liabilities
- $243.5M
- Current liabilities
- $129.8M
- Shareholders’ equity
- $189.5M
Cash flow
- Operating cash flow
- -$5.6M
- Investing cash flow
- -$30.3M
- Financing cash flow
- $7.0M
- Net cash flow
- -$28.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.7B
- EPS (diluted)
- $-0.13
- Shares outstanding
- 123.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 31, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $16.1M in FY2025.
- Gross margin of 90.2%, net margin -4.3%.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Arcutis Biotherapeutics, Inc..
Write a review
News about Arcutis Biotherapeutics, Inc.
News & sentiment via Polygon.io
